C. Difficile: Trials, Treatments and New Guidelines
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
C. Difficile Spores Valerate + Clindamycin C
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/114080/ This is the author’s version of a work that was submitted to / accepted for publication. Citation for final published version: McDonald, Julie A.K., Mullish, Benjamin H., Pechlivanis, Alexandros, Liu, Zhigang, Brignardello, Jerusa, Kao, Dina, Holmes, Elaine, Li, Jia V., Clarke, Thomas B., Thursz, Mark R. and Marchesi, Julian R. 2018. Inhibiting growth of Clostridioides difficile by restoring valerate, produced by the intestinal microbiota. Gastroenterology 155 (5) , pp. 1495-1507. 10.1053/j.gastro.2018.07.014 file Publishers page: http://dx.doi.org/10.1053/j.gastro.2018.07.014 <http://dx.doi.org/10.1053/j.gastro.2018.07.014> Please note: Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper. This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders. Accepted Manuscript Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota Julie A.K. McDonald, Benjamin H. Mullish, Alexandros Pechlivanis, Zhigang Liu, Jerusa Brignardello, Dina Kao, -
High-Quality Draft Genome Sequences of Five Anaerobic Oral Bacteria and Description of Peptoanaerobacter Stomatis Gen
Sizova et al. Standards in Genomic Sciences (2015) 10:37 DOI 10.1186/s40793-015-0027-8 EXTENDED GENOME REPORT Open Access High-quality draft genome sequences of five anaerobic oral bacteria and description of Peptoanaerobacter stomatis gen. nov., sp. nov., a new member of the family Peptostreptococcaceae Maria V. Sizova1, Amanda Chilaka1, Ashlee M. Earl2, Sebastian N. Doerfert1, Paul A. Muller1, Manolito Torralba3, Jamison M. McCorrison3, A. Scott Durkin3, Karen E. Nelson3 and Slava S. Epstein1* Abstract Here we report a summary classification and the features of five anaerobic oral bacteria from the family Peptostreptococcaceae. Bacterial strains were isolated from human subgingival plaque. Strains ACC19a, CM2, CM5, and OBRC8 represent the first known cultivable members of “yet uncultured” human oral taxon 081; strain AS15 belongs to “cultivable” human oral taxon 377. Based on 16S rRNA gene sequence comparisons, strains ACC19a, CM2, CM5, and OBRC8 are distantly related to Eubacterium yurii subs. yurii and Filifactor alocis, with 93.2 – 94.4 % and 85.5 % of sequence identity, respectively. The genomes of strains ACC19a, CM2, CM5, OBRC8 and AS15 are 2,541,543; 2,312,592; 2,594,242; 2,553,276; and 2,654,638 bp long. The genomes are comprised of 2277, 1973, 2325, 2277, and 2308 protein-coding genes and 54, 57, 54, 36, and 28 RNA genes, respectively. Based on the distinct characteristics presented here, we suggest that strains ACC19a, CM2, CM5, and OBRC8 represent a novel genus and species within the family Peptostreptococcaceae, for which we propose the name Peptoanaerobacter stomatis gen. nov., sp. nov. The type strain is strain ACC19aT (=HM-483T; =DSM 28705T;=ATCC BAA-2665T). -
Mortality Following Clostridioides Difficile Infection in Europe: a Retrospective Multicenter Case-Control Study
antibiotics Article Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study Jacek Czepiel 1,* , Marcela Krutova 2,3, Assaf Mizrahi 3,4,5 , Nagham Khanafer 3,6,7, David A. Enoch 8, Márta Patyi 9, Aleksander Deptuła 10, Antonella Agodi 11 , Xavier Nuvials 12 , Hanna Pituch 3,13 , Małgorzata Wójcik-Bugajska 14, Iwona Filipczak-Bryniarska 15, Bartosz Brzozowski 16, Marcin Krzanowski 17, Katarzyna Konturek 18, Marcin Fedewicz 19, Mateusz Michalak 20, Lorra Monpierre 4, Philippe Vanhems 6,7, Theodore Gouliouris 8, Artur Jurczyszyn 21, Sarah Goldman-Mazur 21, Dorota Wulta ´nska 13 , Ed J. Kuijper 3,22,23, Jan Skupie ´n 24, Grazyna˙ Biesiada 1 and Aleksander Garlicki 1 1 Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, 30-688 Krakow, Poland; [email protected] (G.B.); [email protected] (A.G.) 2 Department of Medical Microbiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, 15006 Prague, Czech Republic; [email protected] or [email protected] 3 ESCMID Study Group for Clostridioides Difficile (ESGCD), 4001 Basel, Switzerland; [email protected] (A.M.); [email protected] (N.K.); [email protected] (H.P.); [email protected] (E.J.K.) 4 Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, 75014 Paris, France; [email protected] 5 Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, 92290 Châtenay Malabry, France 6 Unité d’Hygiène, Epidémiologie -
Cadazolid/ACT-179811 Protocol AC-061A301
Cadazolid/ACT-179811 Protocol AC-061A301 A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD) NCT Number NCT01987895 Document Version, Date Final Version 3, 22 October 2015 Document History: - Original Version 29 August 2013 - Amendment 1 11 December 2014 - Amendment 2 22 October 2015 Main reason for Amendment 1 The main analysis of the primary endpoint Clinical Cure will be conducted on two co-primary analysis sets (i.e., modified intent-to-treat [mITT] analysis set and Per-protocol analysis set [PPS]) instead of sequential analysis. Further changes include the addition of an emerging hypervirulent Clostridium difficile strain, the addition of endpoints related to susceptibility testing of C. difficile and vancomycin-resistant enterococci, and general clarifications of eligibility criteria and statistical analyses including a modification to the definition of recurrence for analyses of secondary variable sustained cure rate. Main reason for Amendment 2 To remove the interim analysis originally planned after the randomization of 67% of the subjects. Confidentiality statement Property of Actelion Pharmaceuticals Ltd. May not be used, divulged, published or otherwise disclosed without the consent of Actelion Pharmaceuticals Ltd Cadazolid/ACT-179811 EudraCT: 2013-002528-17 Clostridium difficile-associated diarrhea Doc No D-15.418 Protocol AC-061A301 Confidential Version 3 22 October 2015, page 2/138 SPONSOR CONTACT DETAILS SPONSOR ACTELION Pharmaceuticals Ltd Gewerbestrasse 16 CH-4123 Allschwil Switzerland Clinical Trial Physician MEDICAL HOTLINE Toll phone number: +41 61 227 05 63 Site-specific toll telephone numbers and toll-free numbers for the Medical Hotline can be found in the Investigator Site File. -
Management of Adult Clostridium Difficile Digestive Contaminations: a Literature Review
European Journal of Clinical Microbiology & Infectious Diseases (2019) 38:209–231 https://doi.org/10.1007/s10096-018-3419-z REVIEW Management of adult Clostridium difficile digestive contaminations: a literature review Fanny Mathias1 & Christophe Curti1,2 & Marc Montana1,3 & Charléric Bornet4 & Patrice Vanelle 1,2 Received: 5 October 2018 /Accepted: 30 October 2018 /Published online: 29 November 2018 # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Clostridium difficile infections (CDI) dramatically increased during the last decade and cause a major public health problem. Current treatments are limited by the high disease recurrence rate, severity of clinical forms, disruption of the gut microbiota, and colonization by vancomycin-resistant enterococci (VRE). In this review, we resumed current treatment options from official recommendation to promising alternatives available in the management of adult CDI, with regard to severity and recurring or non-recurring character of the infection. Vancomycin remains the first-line antibiotic in the management of mild to severe CDI. The use of metronidazole is discussed following the latest US recommendations that replaced it by fidaxomicin as first-line treatment of an initial episode of non-severe CDI. Fidaxomicin, the most recent antibiotic approved for CDI in adults, has several advantages compared to vancomycin and metronidazole, but its efficacy seems limited in cases of multiple recurrences. Innovative therapies such as fecal microbiota transplantation (FMT) and antitoxin antibodies were developed to limit the occurrence of recurrence of CDI. Research is therefore very active, and new antibiotics are being studied as surotomycin, cadazolid, and rinidazole. Keywords Clostridiumdifficile .Fidaxomicin .Fecalmicrobiotatransplantation .Antitoxinantibodies .Surotomycin .Cadazolid Introduction (Fig. -
Current Trends of Enterococci in Dairy Products: a Comprehensive Review of Their Multiple Roles
foods Review Current Trends of Enterococci in Dairy Products: A Comprehensive Review of Their Multiple Roles Maria de Lurdes Enes Dapkevicius 1,2,* , Bruna Sgardioli 1,2 , Sandra P. A. Câmara 1,2, Patrícia Poeta 3,4 and Francisco Xavier Malcata 5,6,* 1 Faculty of Agricultural and Environmental Sciences, University of the Azores, 9700-042 Angra do Heroísmo, Portugal; [email protected] (B.S.); [email protected] (S.P.A.C.) 2 Institute of Agricultural and Environmental Research and Technology (IITAA), University of the Azores, 9700-042 Angra do Heroísmo, Portugal 3 Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), 5001-801 Vila Real, Portugal; [email protected] 4 Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, 2829-516 Lisboa, Portugal 5 LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, 420-465 Porto, Portugal 6 FEUP—Faculty of Engineering, University of Porto, 4200-465 Porto, Portugal * Correspondence: [email protected] (M.d.L.E.D.); [email protected] (F.X.M.) Abstract: As a genus that has evolved for resistance against adverse environmental factors and that readily exchanges genetic elements, enterococci are well adapted to the cheese environment and may reach high numbers in artisanal cheeses. Their metabolites impact cheese flavor, texture, Citation: Dapkevicius, M.d.L.E.; and rheological properties, thus contributing to the development of its typical sensorial properties. Sgardioli, B.; Câmara, S.P.A.; Poeta, P.; Due to their antimicrobial activity, enterococci modulate the cheese microbiota, stimulate autoly- Malcata, F.X. -
Oral Administration of Lactobacillus Gasseri SBT2055 Is Effective In
www.nature.com/scientificreports OPEN Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas Received: 23 June 2015 Accepted: 7 March 2017 gingivalis-accelerated periodontal Published: xx xx xxxx disease R. Kobayashi1, T. Kobayashi2, F. Sakai3, T. Hosoya3, M. Yamamoto1 & T. Kurita-Ochiai1 Probiotics have been used to treat gastrointestinal disorders. However, the effect of orally intubated probiotics on oral disease remains unclear. We assessed the potential of oral administration of Lactobacillus gasseri SBT2055 (LG2055) for Porphyromonas gingivalis infection. LG2055 treatment significantly reduced alveolar bone loss, detachment and disorganization of the periodontal ligament, and bacterial colonization by subsequent P. gingivalis challenge. Furthermore, the expression and secretion of TNF-α and IL-6 in gingival tissue was significantly decreased in LG2055-administered mice after bacterial infection. Conversely, mouse β-defensin-14 (mBD-14) mRNA and its peptide products were significantly increased in distant mucosal components as well as the intestinal tract to which LG2055 was introduced. Moreover, IL-1β and TNF-α production from THP-1 monocytes stimulated with P. gingivalis antigen was significantly reduced by the addition of humanβ -defensin-3. These results suggest that gastrically administered LG2055 can enhance immunoregulation followed by periodontitis prevention in oral mucosa via the gut immune system; i.e., the possibility of homing in innate immunity. Porphyromonas gingivalis, a Gram-negative anaerobe, is one of the major pathogens associated with chronic periodontitis, a disease that causes the destruction of alveolar bone, and, as a consequence, tooth loss1. Recent evidence suggests that this bacterium contributes to periodontitis by functioning as a keystone pathogen2, 3. -
Sporulation Evolution and Specialization in Bacillus
bioRxiv preprint doi: https://doi.org/10.1101/473793; this version posted March 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Research article From root to tips: sporulation evolution and specialization in Bacillus subtilis and the intestinal pathogen Clostridioides difficile Paula Ramos-Silva1*, Mónica Serrano2, Adriano O. Henriques2 1Instituto Gulbenkian de Ciência, Oeiras, Portugal 2Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal *Corresponding author: Present address: Naturalis Biodiversity Center, Marine Biodiversity, Leiden, The Netherlands Phone: 0031 717519283 Email: [email protected] (Paula Ramos-Silva) Running title: Sporulation from root to tips Keywords: sporulation, bacterial genome evolution, horizontal gene transfer, taxon- specific genes, Bacillus subtilis, Clostridioides difficile 1 bioRxiv preprint doi: https://doi.org/10.1101/473793; this version posted March 11, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Abstract Bacteria of the Firmicutes phylum are able to enter a developmental pathway that culminates with the formation of a highly resistant, dormant spore. Spores allow environmental persistence, dissemination and for pathogens, are infection vehicles. In both the model Bacillus subtilis, an aerobic species, and in the intestinal pathogen Clostridioides difficile, an obligate anaerobe, sporulation mobilizes hundreds of genes. -
Antimicrobial Resistance in Companion Animal Pathogens in Australia and Assessment of Pradofloxacin on the Gut Microbiota
Antimicrobial resistance in companion animal pathogens in Australia and assessment of pradofloxacin on the gut microbiota Sugiyono Saputra A thesis submitted in fulfilment of the requirements of the degree of Doctor of Philosophy School of Animal and Veterinary Sciences The University of Adelaide February 2018 Table of Contents Thesis Declaration ...................................................................................................................... iii Dedication ................................................................................................................................. iv Acknowledgement ...................................................................................................................... v Preamble .................................................................................................................................... vi List of Publications ..................................................................................................................... vii Abstract .......................................................................................................................................ix Chapter 1 General Introduction ................................................................................................. 1 1.1. Antimicrobials and their consequences ............................................................................ 2 1.2. The emergence and monitoring AMR................................................................................ 2 -
WO 2018/064165 A2 (.Pdf)
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/064165 A2 05 April 2018 (05.04.2018) W !P O PCT (51) International Patent Classification: Published: A61K 35/74 (20 15.0 1) C12N 1/21 (2006 .01) — without international search report and to be republished (21) International Application Number: upon receipt of that report (Rule 48.2(g)) PCT/US2017/053717 — with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 27 September 2017 (27.09.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 62/400,372 27 September 2016 (27.09.2016) US 62/508,885 19 May 2017 (19.05.2017) US 62/557,566 12 September 2017 (12.09.2017) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSI¬ TY OF TEXAS SYSTEM [US/US]; 210 West 7th St., Austin, TX 78701 (US). (72) Inventors: WARGO, Jennifer; 1814 Bissonnet St., Hous ton, TX 77005 (US). GOPALAKRISHNAN, Vanch- eswaran; 7900 Cambridge, Apt. 10-lb, Houston, TX 77054 (US). (74) Agent: BYRD, Marshall, P.; Parker Highlander PLLC, 1120 S. Capital Of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
Bacteriocin‐Like Inhibitory Activities of Seven Lactobacillus Delbrueckii
Letters in Applied Microbiology ISSN 0266-8254 ORIGINAL ARTICLE Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains L. Boyanova, G. Gergova, R. Markovska, D. Yordanov and I. Mitov Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria Significance and Impact of the Study: In this study, anti-Helicobacter pylori activity of seven Lactobacil- lus delbrueckii subsp. bulgaricus (GLB) strains was evaluated by four cell-free supernatant (CFS) types. The GLB strains produced heat-stable bacteriocin-like inhibitory substances (BLISs) with a strong anti-H. pylori activity and some neutralized, catalase- and heat-treated CFSs inhibited >83% of the test strains. Bacteriocin-like inhibitory substance production of GLB strains can render them valuable probiotics in the control of H. pylori infection. Keywords Abstract antibiotics, bacteriocins, Helicobacter, Lactobacillus, probiotics. The aim of the study was to detect anti-Helicobacter pylori activity of seven Lactobacillus delbrueckii subsp. bulgaricus (GLB) strains by four cell-free Correspondence supernatant (CFS) types. Activity of non-neutralized and non-heat-treated Lyudmila Boyanova, Department of Medical (CFSs1), non-neutralized and heat-treated (CFSs2), pH neutralized, catalase- Microbiology, Medical University of Sofia, treated and non-heat-treated (CFSs3), or neutralized, catalase- and heat-treated Zdrave Street 2, 1431 Sofia, Bulgaria. (CFSs4) CFSs against 18 H. pylori strains (11 of which with antibiotic E-mail: [email protected] resistance) was evaluated. All GLB strains produced bacteriocin-like inhibitory 2017/1069: received 3 June 2017, revised 27 substances (BLISs), the neutralized CFSs of two GLB strains inhibited >81% of August 2017 and accepted 25 September test strains and those of four GLB strains were active against >71% of 2017 antibiotic resistant strains. -
Targeting Virulence Not Viability in the Search for Future Antibacterials
Targeting Virulence not Viability in the Search for Future Antibacterials 1 Begoña Heras1#, Martin J. Scanlon2,3# and Jennifer L. Martin4#* 1La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086 Australia 2Faculty of Pharmacy and Pharmaceutical Sciences, Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052 Australia 3ARC Centre of Excellence for Coherent X-ray Science, Monash University, Parkville, VIC 3052 Australia 4The University of Queensland, Institute for Molecular Bioscience, Division of Article Chemistry and Structural Biology, Brisbane, QLD 4072 Australia #Contributed equally * To whom correspondence should be addressed: Email: [email protected] Phone +61 7 3346 2016 Running Head: Antivirulence Strategies for Bacterial Infection Keywords: Antivirulence; antibacterial; bacterial infection, pilicide, quorum sensing Word Count (excluding title page, summary, references, tables, figures) 2405 Number of Tables: 1 Number of Figures: 3 This article has been accepted for publication and undergone full peer review but has not been through theAccepted copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bcp.12356 1 This article is protected by copyright. All rights reserved. ABSTRACT New antibacterials need new approaches to overcome the problem of rapid antibiotic resistance. Here we review the development of potential new antibacterial drugs that do not kill bacteria or inhibit their growth, but combat disease instead by targeting bacterial virulence. INTRODUCTION In the ongoing battle between people and pathogens, the pendulum seems to be swingingArticle in favour of the bugs.